{"transactions":[{"id":4629432,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Restricted Shares","published_at":"2026-10-05T16:18:10.000Z","date":"2026-10-01","kind":"exercise","planned":false,"acquired":false,"shares":700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."}],"balance_after":250,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":700},"source":{"system":"sec-edgar","filing":"0001193125-26-413742","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1958086/000119312526413742/ownership.xml","form_type":"4"}},{"id":4629431,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Common Stock","published_at":"2026-10-05T16:18:10.000Z","date":"2026-10-01","kind":"exercise","planned":false,"acquired":true,"shares":700,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":28364.621,"source":{"system":"sec-edgar","filing":"0001193125-26-413742","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1958086/000119312526413742/ownership.xml","form_type":"4"}},{"id":4629430,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Common Stock","published_at":"2026-10-05T16:18:10.000Z","date":"2026-10-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":276,"price":9.76,"value":2693.76,"ownership":{"direct":true},"balance_after":28088.621,"source":{"system":"sec-edgar","filing":"0001193125-26-413742","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1958086/000119312526413742/ownership.xml","form_type":"4"}},{"id":4629428,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Restricted Shares","published_at":"2026-10-05T16:17:23.000Z","date":"2026-10-01","kind":"exercise","planned":false,"acquired":false,"shares":250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Multiple restricted share grants are included in this total."}],"balance_after":6000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":250},"source":{"system":"sec-edgar","filing":"0001193125-26-413736","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000119312526413736/ownership.xml","form_type":"4"}},{"id":4629427,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Common Stock","published_at":"2026-10-05T16:17:23.000Z","date":"2026-10-01","kind":"exercise","planned":false,"acquired":true,"shares":250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8917.334,"source":{"system":"sec-edgar","filing":"0001193125-26-413736","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000119312526413736/ownership.xml","form_type":"4"}},{"id":4629426,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Common Stock","published_at":"2026-10-05T16:17:23.000Z","date":"2026-10-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":99,"price":9.76,"value":966.24,"ownership":{"direct":true},"balance_after":8818.334,"source":{"system":"sec-edgar","filing":"0001193125-26-413736","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000119312526413736/ownership.xml","form_type":"4"}},{"id":696775,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26546,"kind":"person","name":"Bruno Lawrence","position":1,"cik":"0001730336","reported_name":"Bruno Lawrence","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2026-08-04T14:40:31.000Z","date":"2026-07-31","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":10.78,"value":53900.0,"ownership":{"direct":true},"balance_after":262438,"source":{"system":"sec-edgar","filing":"0001193125-26-331852","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730336/000119312526331852/ownership.xml","form_type":"4"}},{"id":697502,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Restricted Shares","published_at":"2026-08-04T14:36:22.000Z","date":"2026-08-01","kind":"exercise","planned":false,"acquired":false,"shares":200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Multiple restricted share grants are included in this total."}],"balance_after":6490,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":200},"source":{"system":"sec-edgar","filing":"0001193125-26-331843","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000119312526331843/ownership.xml","form_type":"4"}},{"id":697501,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Restricted Shares","published_at":"2026-08-04T14:36:22.000Z","date":"2026-08-01","kind":"exercise","planned":false,"acquired":false,"shares":240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Multiple restricted share grants are included in this total."}],"balance_after":6250,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":240},"source":{"system":"sec-edgar","filing":"0001193125-26-331843","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000119312526331843/ownership.xml","form_type":"4"}},{"id":697500,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Common Stock","published_at":"2026-08-04T14:36:22.000Z","date":"2026-08-01","kind":"exercise","planned":false,"acquired":true,"shares":200,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8625.334,"source":{"system":"sec-edgar","filing":"0001193125-26-331843","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000119312526331843/ownership.xml","form_type":"4"}},{"id":697499,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Common Stock","published_at":"2026-08-04T14:36:22.000Z","date":"2026-08-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":90,"price":10.64,"value":957.6,"ownership":{"direct":true},"balance_after":8535.334,"source":{"system":"sec-edgar","filing":"0001193125-26-331843","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000119312526331843/ownership.xml","form_type":"4"}},{"id":697498,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Common Stock","published_at":"2026-08-04T14:36:22.000Z","date":"2026-08-01","kind":"exercise","planned":false,"acquired":true,"shares":240,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8775.334,"source":{"system":"sec-edgar","filing":"0001193125-26-331843","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000119312526331843/ownership.xml","form_type":"4"}},{"id":697497,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Common Stock","published_at":"2026-08-04T14:36:22.000Z","date":"2026-08-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":108,"price":10.64,"value":1149.12,"ownership":{"direct":true},"balance_after":8667.334,"source":{"system":"sec-edgar","filing":"0001193125-26-331843","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000119312526331843/ownership.xml","form_type":"4"}},{"id":697378,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Restricted Shares","published_at":"2026-08-04T14:27:07.000Z","date":"2026-08-01","kind":"exercise","planned":false,"acquired":false,"shares":250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Multiple restricted share grants are included in this total."}],"balance_after":950,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":250},"source":{"system":"sec-edgar","filing":"0001193125-26-331829","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1872069/000119312526331829/ownership.xml","form_type":"4"}},{"id":697377,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Common Stock","published_at":"2026-08-04T14:27:07.000Z","date":"2026-08-01","kind":"exercise","planned":false,"acquired":true,"shares":250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":27763.621,"source":{"system":"sec-edgar","filing":"0001193125-26-331829","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1872069/000119312526331829/ownership.xml","form_type":"4"}},{"id":697376,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Common Stock","published_at":"2026-08-04T14:27:07.000Z","date":"2026-08-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":99,"price":10.64,"value":1053.36,"ownership":{"direct":true},"balance_after":27664.621,"source":{"system":"sec-edgar","filing":"0001193125-26-331829","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872069/000119312526331829/ownership.xml","form_type":"4"}},{"id":793964,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Restricted Shares","published_at":"2026-05-04T20:37:33.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":false,"shares":250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Multiple restricted share grants are included in this total."}],"balance_after":1200,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":250},"source":{"system":"sec-edgar","filing":"0001193125-26-204136","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1872069/000119312526204136/ownership.xml","form_type":"4"}},{"id":793963,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Common Stock","published_at":"2026-05-04T20:37:33.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":true,"shares":250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":27610.621,"source":{"system":"sec-edgar","filing":"0001193125-26-204136","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1872069/000119312526204136/ownership.xml","form_type":"4"}},{"id":793962,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Common Stock","published_at":"2026-05-04T20:37:33.000Z","date":"2026-05-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":97,"price":14.07,"value":1364.79,"ownership":{"direct":true},"balance_after":27513.621,"source":{"system":"sec-edgar","filing":"0001193125-26-204136","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872069/000119312526204136/ownership.xml","form_type":"4"}},{"id":812161,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":49429,"kind":"person","name":"Murray Katherine","position":1,"cik":"0001930744","reported_name":"Murray Katherine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Shares","published_at":"2026-04-08T16:22:35.000Z","date":"2026-04-01","kind":"exercise","planned":false,"acquired":false,"shares":8069,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8069},"source":{"system":"sec-edgar","filing":"0001193125-26-146823","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1930744/000119312526146823/ownership.xml","form_type":"4"}},{"id":812160,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":49429,"kind":"person","name":"Murray Katherine","position":1,"cik":"0001930744","reported_name":"Murray Katherine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Shares","published_at":"2026-04-08T16:22:35.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":7895,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board."}],"balance_after":7895,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7895},"source":{"system":"sec-edgar","filing":"0001193125-26-146823","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1930744/000119312526146823/ownership.xml","form_type":"4"}},{"id":812159,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":49429,"kind":"person","name":"Murray Katherine","position":1,"cik":"0001930744","reported_name":"Murray Katherine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-08T16:22:35.000Z","date":"2026-04-01","kind":"exercise","planned":false,"acquired":true,"shares":8069,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":29290,"source":{"system":"sec-edgar","filing":"0001193125-26-146823","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1930744/000119312526146823/ownership.xml","form_type":"4"}},{"id":813729,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":31865,"kind":"person","name":"ANASTASIO CURT","position":1,"cik":"0001032097","reported_name":"ANASTASIO CURT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Shares","published_at":"2026-04-07T23:47:52.000Z","date":"2026-04-01","kind":"exercise","planned":false,"acquired":false,"shares":8069,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8069},"source":{"system":"sec-edgar","filing":"0001193125-26-145951","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1032097/000119312526145951/ownership.xml","form_type":"4"}},{"id":813728,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":31865,"kind":"person","name":"ANASTASIO CURT","position":1,"cik":"0001032097","reported_name":"ANASTASIO CURT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Shares","published_at":"2026-04-07T23:47:52.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":7895,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board."}],"balance_after":7895,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7895},"source":{"system":"sec-edgar","filing":"0001193125-26-145951","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1032097/000119312526145951/ownership.xml","form_type":"4"}},{"id":813727,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":31865,"kind":"person","name":"ANASTASIO CURT","position":1,"cik":"0001032097","reported_name":"ANASTASIO CURT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-07T23:47:52.000Z","date":"2026-04-01","kind":"exercise","planned":false,"acquired":true,"shares":8069,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":23805,"source":{"system":"sec-edgar","filing":"0001193125-26-145951","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1032097/000119312526145951/ownership.xml","form_type":"4"}},{"id":813098,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":53365,"kind":"person","name":"Klingensmith Harvey Robert","position":1,"cik":"0001800107","reported_name":"Klingensmith Harvey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Shares","published_at":"2026-04-07T23:46:33.000Z","date":"2026-04-01","kind":"exercise","planned":false,"acquired":false,"shares":8069,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8069},"source":{"system":"sec-edgar","filing":"0001193125-26-145945","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1800107/000119312526145945/ownership.xml","form_type":"4"}},{"id":813097,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":53365,"kind":"person","name":"Klingensmith Harvey Robert","position":1,"cik":"0001800107","reported_name":"Klingensmith Harvey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Shares","published_at":"2026-04-07T23:46:33.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":7895,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board."}],"balance_after":7895,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7895},"source":{"system":"sec-edgar","filing":"0001193125-26-145945","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1800107/000119312526145945/ownership.xml","form_type":"4"}},{"id":813096,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":53365,"kind":"person","name":"Klingensmith Harvey Robert","position":1,"cik":"0001800107","reported_name":"Klingensmith Harvey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-07T23:46:33.000Z","date":"2026-04-01","kind":"exercise","planned":false,"acquired":true,"shares":8069,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50031,"source":{"system":"sec-edgar","filing":"0001193125-26-145945","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800107/000119312526145945/ownership.xml","form_type":"4"}},{"id":813076,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":53358,"kind":"person","name":"Temeng Kwaku","position":1,"cik":"0001846675","reported_name":"Temeng Kwaku","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Shares","published_at":"2026-04-07T23:45:05.000Z","date":"2026-04-01","kind":"exercise","planned":false,"acquired":false,"shares":8069,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8069},"source":{"system":"sec-edgar","filing":"0001193125-26-145942","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1846675/000119312526145942/ownership.xml","form_type":"4"}},{"id":813075,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":53358,"kind":"person","name":"Temeng Kwaku","position":1,"cik":"0001846675","reported_name":"Temeng Kwaku","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Shares","published_at":"2026-04-07T23:45:05.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":7895,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board."}],"balance_after":7895,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7895},"source":{"system":"sec-edgar","filing":"0001193125-26-145942","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1846675/000119312526145942/ownership.xml","form_type":"4"}},{"id":813074,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":53358,"kind":"person","name":"Temeng Kwaku","position":1,"cik":"0001846675","reported_name":"Temeng Kwaku","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-07T23:45:05.000Z","date":"2026-04-01","kind":"exercise","planned":false,"acquired":true,"shares":8069,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":33597,"source":{"system":"sec-edgar","filing":"0001193125-26-145942","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1846675/000119312526145942/ownership.xml","form_type":"4"}},{"id":813235,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":53387,"kind":"person","name":"MARTINOVICH ROBERT F","position":1,"cik":"0001251674","reported_name":"MARTINOVICH ROBERT F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Shares","published_at":"2026-04-07T23:43:37.000Z","date":"2026-04-01","kind":"exercise","planned":false,"acquired":false,"shares":8069,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8069},"source":{"system":"sec-edgar","filing":"0001193125-26-145939","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1251674/000119312526145939/ownership.xml","form_type":"4"}},{"id":813234,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":53387,"kind":"person","name":"MARTINOVICH ROBERT F","position":1,"cik":"0001251674","reported_name":"MARTINOVICH ROBERT F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Shares","published_at":"2026-04-07T23:43:37.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":7895,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board."}],"balance_after":7895,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7895},"source":{"system":"sec-edgar","filing":"0001193125-26-145939","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1251674/000119312526145939/ownership.xml","form_type":"4"}},{"id":813233,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":53387,"kind":"person","name":"MARTINOVICH ROBERT F","position":1,"cik":"0001251674","reported_name":"MARTINOVICH ROBERT F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-07T23:43:37.000Z","date":"2026-04-01","kind":"exercise","planned":false,"acquired":true,"shares":8069,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8069,"source":{"system":"sec-edgar","filing":"0001193125-26-145939","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1251674/000119312526145939/ownership.xml","form_type":"4"}},{"id":813438,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":46460,"kind":"person","name":"Carnes Martha Z.","position":1,"cik":"0001678397","reported_name":"Carnes Martha Z.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Shares","published_at":"2026-04-07T23:41:50.000Z","date":"2026-04-01","kind":"exercise","planned":false,"acquired":false,"shares":8069,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8069},"source":{"system":"sec-edgar","filing":"0001193125-26-145937","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1678397/000119312526145937/ownership.xml","form_type":"4"}},{"id":813437,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":46460,"kind":"person","name":"Carnes Martha Z.","position":1,"cik":"0001678397","reported_name":"Carnes Martha Z.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Shares","published_at":"2026-04-07T23:41:50.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":7895,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board."}],"balance_after":7895,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7895},"source":{"system":"sec-edgar","filing":"0001193125-26-145937","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678397/000119312526145937/ownership.xml","form_type":"4"}},{"id":813436,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":46460,"kind":"person","name":"Carnes Martha Z.","position":1,"cik":"0001678397","reported_name":"Carnes Martha Z.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-07T23:41:50.000Z","date":"2026-04-01","kind":"exercise","planned":false,"acquired":true,"shares":8069,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":54397,"source":{"system":"sec-edgar","filing":"0001193125-26-145937","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678397/000119312526145937/ownership.xml","form_type":"4"}},{"id":901260,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Performance Shares","published_at":"2026-02-17T16:07:05.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":33490,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award vests following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the \"Performance Period\"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on December 31, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (\"ROIC\") among the Bloomberg Peer Group (\"BPG\"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile of ROIC (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile of ROIC (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This award vests following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the \"Performance Period\"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on December 31, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (\"ROIC\") among the Bloomberg Peer Group (\"BPG\"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period."}],"balance_after":33490,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":33490},"source":{"system":"sec-edgar","filing":"0001193125-26-053614","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872069/000119312526053614/ownership.xml","form_type":"4"}},{"id":900284,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26546,"kind":"person","name":"Bruno Lawrence","position":1,"cik":"0001730336","reported_name":"Bruno Lawrence","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Performance Shares","published_at":"2026-02-17T16:02:34.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":204340,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award vests following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the \"Performance Period\"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on December 31, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (\"ROIC\") among the Bloomberg Peer Group (\"BPG\"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile of ROIC (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile of ROIC (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This award vests following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the \"Performance Period\"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on December 31, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (\"ROIC\") among the Bloomberg Peer Group (\"BPG\"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period."}],"balance_after":204340,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":204340},"source":{"system":"sec-edgar","filing":"0001193125-26-053588","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730336/000119312526053588/ownership.xml","form_type":"4"}},{"id":901401,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Performance Shares","published_at":"2026-02-17T16:00:39.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":7526,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Assuming the recipient's continued employment (or death or disability while employed) and the satisfaction of certain performances criteria set forth below, this award will vest on December 31, 2028, following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the \"Performance Period\"). At the end of the Perofrmance Period, 100% of the award will vest if the Company is in the top 55th percentile of Return on Invested Capital (\"ROIC\") among the Bloomberg Peer Group (\"BPG\"), and 200% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 55th and 85th percentile of ROIC (equivalent to 100% up to 200% of the award)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Assuming the recipient's continued employment (or death or disability while employed) and the satisfaction of certain performances criteria set forth below, this award will vest on December 31, 2028, following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the \"Performance Period\"). At the end of the Perofrmance Period, 100% of the award will vest if the Company is in the top 55th percentile of Return on Invested Capital (\"ROIC\") among the Bloomberg Peer Group (\"BPG\"), and 200% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 55th and 85th percentile of ROIC (equivalent to 100% up to 200% of the award)."}],"balance_after":7526,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7526},"source":{"system":"sec-edgar","filing":"0001193125-26-053572","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000119312526053572/ownership.xml","form_type":"4"}},{"id":900257,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Gresham Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Performance Shares","published_at":"2026-02-17T11:06:09.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":33490,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award vests following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the \"Performance Period\"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on December 31, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (\"ROIC\") among the Bloomberg Peer Group (\"BPG\"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile of ROIC (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile of ROIC (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This award vests following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the \"Performance Period\"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on December 31, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (\"ROIC\") among the Bloomberg Peer Group (\"BPG\"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period."}],"balance_after":33490,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":33490},"source":{"system":"sec-edgar","filing":"0001193125-26-053610","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1842114/000119312526053610/ownership.xml","form_type":"4"}},{"id":900317,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":66149,"kind":"person","name":"Hill Christopher Scott","position":1,"cik":"0001641315","reported_name":"Hill Christopher Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CFO"}}],"security":"Performance Shares","published_at":"2026-02-17T11:04:01.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":70008,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This award vests following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the \"Performance Period\"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on December 31, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (\"ROIC\") among the Bloomberg Peer Group (\"BPG\"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile of ROIC (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile of ROIC (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This award vests following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the \"Performance Period\"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on December 31, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (\"ROIC\") among the Bloomberg Peer Group (\"BPG\"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period."}],"balance_after":70008,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":70008},"source":{"system":"sec-edgar","filing":"0001193125-26-053598","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1641315/000119312526053598/ownership.xml","form_type":"4"}},{"id":951945,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Performance Shares","published_at":"2026-01-05T20:18:37.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":false,"shares":24952,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares were awarded as restricted performance shares in February 2023, as disclosed in the Reporting Person's Form 4 filing on February 21, 2023. The Company finished in the 68th percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2025. Therefore, the performance criteria and requirements for vesting have been satisfied at 116.5% of the target award level, and such number of shares vested on December 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares were awarded as restricted performance shares in February 2023, as disclosed in the Reporting Person's Form 4 filing on February 21, 2023. The Company finished in the 68th percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2025. Therefore, the performance criteria and requirements for vesting have been satisfied at 116.5% of the target award level, and such number of shares vested on December 31, 2025."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":24952},"source":{"system":"sec-edgar","filing":"0001193125-26-002257","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1872069/000119312526002257/ownership.xml","form_type":"4"}},{"id":951944,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Common Stock","published_at":"2026-01-05T20:18:37.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":true,"shares":24952,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":41670.621,"source":{"system":"sec-edgar","filing":"0001193125-26-002257","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1872069/000119312526002257/ownership.xml","form_type":"4"}},{"id":951943,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Common Stock","published_at":"2026-01-05T20:18:37.000Z","date":"2025-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":14310,"price":16.03,"value":229389.3,"ownership":{"direct":true},"balance_after":27360.621,"source":{"system":"sec-edgar","filing":"0001193125-26-002257","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872069/000119312526002257/ownership.xml","form_type":"4"}},{"id":949837,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26546,"kind":"person","name":"Bruno Lawrence","position":1,"cik":"0001730336","reported_name":"Bruno Lawrence","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Performance Shares","published_at":"2026-01-05T20:16:13.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":false,"shares":180722,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares were awarded as restricted performance shares in February 2023, as disclosed in the Reporting Person's Form 4 filing on February 21, 2023. The Company finished in the 68th percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2025. Therefore, the performance criteria and requirements for vesting have been satisfied at 116.5% of the target award level, and such number of shares vested on December 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares were awarded as restricted performance shares in February 2023, as disclosed in the Reporting Person's Form 4 filing on February 21, 2023. The Company finished in the 68th percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2025. Therefore, the performance criteria and requirements for vesting have been satisfied at 116.5% of the target award level, and such number of shares vested on December 31, 2025."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":180722},"source":{"system":"sec-edgar","filing":"0001193125-26-002248","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1730336/000119312526002248/ownership.xml","form_type":"4"}},{"id":949836,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26546,"kind":"person","name":"Bruno Lawrence","position":1,"cik":"0001730336","reported_name":"Bruno Lawrence","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2026-01-05T20:16:13.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":true,"shares":180722,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":370119,"source":{"system":"sec-edgar","filing":"0001193125-26-002248","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1730336/000119312526002248/ownership.xml","form_type":"4"}},{"id":949835,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26546,"kind":"person","name":"Bruno Lawrence","position":1,"cik":"0001730336","reported_name":"Bruno Lawrence","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2026-01-05T20:16:13.000Z","date":"2025-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":112681,"price":16.03,"value":1806276.43,"ownership":{"direct":true},"balance_after":257438,"source":{"system":"sec-edgar","filing":"0001193125-26-002248","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730336/000119312526002248/ownership.xml","form_type":"4"}},{"id":949721,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Gresham Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Performance Shares","published_at":"2026-01-05T15:18:06.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":false,"shares":24952,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares were awarded as restricted performance shares in February 2023, as disclosed in the Reporting Person's Form 4 filing on February 21, 2023. The Company finished in the 68th percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2025. Therefore, the performance criteria and requirements for vesting have been satisfied at 116.5% of the target award level, and such number of shares vested on December 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares were awarded as restricted performance shares in February 2023, as disclosed in the Reporting Person's Form 4 filing on February 21, 2023. The Company finished in the 68th percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2025. Therefore, the performance criteria and requirements for vesting have been satisfied at 116.5% of the target award level, and such number of shares vested on December 31, 2025."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":24952},"source":{"system":"sec-edgar","filing":"0001193125-26-002254","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1842114/000119312526002254/ownership.xml","form_type":"4"}},{"id":949720,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Gresham Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Common Stock","published_at":"2026-01-05T15:18:06.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":true,"shares":24952,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":52527,"source":{"system":"sec-edgar","filing":"0001193125-26-002254","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1842114/000119312526002254/ownership.xml","form_type":"4"}},{"id":949719,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":66141,"kind":"person","name":"Gresham Gwendolyn","position":1,"cik":"0001842114","reported_name":"Gresham Gwendolyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Common Stock","published_at":"2026-01-05T15:18:06.000Z","date":"2025-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":19301,"price":16.03,"value":309395.03,"ownership":{"direct":true},"balance_after":33226,"source":{"system":"sec-edgar","filing":"0001193125-26-002254","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1842114/000119312526002254/ownership.xml","form_type":"4"}},{"id":949930,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":66149,"kind":"person","name":"Hill Christopher Scott","position":1,"cik":"0001641315","reported_name":"Hill Christopher Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CFO"}}],"security":"Performance Shares","published_at":"2026-01-05T15:17:09.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":false,"shares":61417,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares were awarded as restricted performance shares in February 2023, as disclosed in the Reporting Person's Form 4 filing on February 21, 2023. The Company finished in the 68th percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2025. Therefore, the performance criteria and requirements for vesting have been satisfied at 116.5% of the target award level, and such number of shares vested on December 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares were awarded as restricted performance shares in February 2023, as disclosed in the Reporting Person's Form 4 filing on February 21, 2023. The Company finished in the 68th percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2025. Therefore, the performance criteria and requirements for vesting have been satisfied at 116.5% of the target award level, and such number of shares vested on December 31, 2025."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":61417},"source":{"system":"sec-edgar","filing":"0001193125-26-002252","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1641315/000119312526002252/ownership.xml","form_type":"4"}},{"id":949929,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":66149,"kind":"person","name":"Hill Christopher Scott","position":1,"cik":"0001641315","reported_name":"Hill Christopher Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CFO"}}],"security":"Common Stock","published_at":"2026-01-05T15:17:09.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":true,"shares":61417,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":142354,"source":{"system":"sec-edgar","filing":"0001193125-26-002252","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1641315/000119312526002252/ownership.xml","form_type":"4"}},{"id":949928,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":66149,"kind":"person","name":"Hill Christopher Scott","position":1,"cik":"0001641315","reported_name":"Hill Christopher Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CFO"}}],"security":"Common Stock","published_at":"2026-01-05T15:17:09.000Z","date":"2025-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":32152,"price":16.03,"value":515396.56,"ownership":{"direct":true},"balance_after":110202,"source":{"system":"sec-edgar","filing":"0001193125-26-002252","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641315/000119312526002252/ownership.xml","form_type":"4"}},{"id":983851,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Restricted Shares","published_at":"2025-12-03T00:35:08.000Z","date":"2025-12-01","kind":"exercise","planned":false,"acquired":false,"shares":864,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Multiple restricted share grants are included in this total."}],"balance_after":6690,"derivative":{"underlying":"Common Stock","underlying_shares":864},"source":{"system":"sec-edgar","filing":"0001193125-25-305634","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000119312525305634/ownership.xml","form_type":"4"}},{"id":983850,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Common Stock","published_at":"2025-12-03T00:35:08.000Z","date":"2025-12-01","kind":"exercise","planned":false,"acquired":true,"shares":864,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8765.334,"source":{"system":"sec-edgar","filing":"0001193125-25-305634","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000119312525305634/ownership.xml","form_type":"4"}},{"id":983849,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Common Stock","published_at":"2025-12-03T00:35:08.000Z","date":"2025-12-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":340,"price":15.39,"value":5232.6,"ownership":{"direct":true},"balance_after":8425.334,"source":{"system":"sec-edgar","filing":"0001193125-25-305634","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000119312525305634/ownership.xml","form_type":"4"}},{"id":1027528,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Restricted Shares","published_at":"2025-10-02T21:16:40.000Z","date":"2025-10-01","kind":"exercise","planned":false,"acquired":false,"shares":700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Multiple restricted share grants are included in this total."}],"balance_after":1450,"derivative":{"underlying":"Common Stock","underlying_shares":700},"source":{"system":"sec-edgar","filing":"0001193125-25-228649","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1872069/000119312525228649/ownership.xml","form_type":"4"}},{"id":1027527,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Common Stock","published_at":"2025-10-02T21:16:40.000Z","date":"2025-10-01","kind":"exercise","planned":false,"acquired":true,"shares":700,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16994.621,"source":{"system":"sec-edgar","filing":"0001193125-25-228649","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1872069/000119312525228649/ownership.xml","form_type":"4"}},{"id":1027526,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Common Stock","published_at":"2025-10-02T21:16:40.000Z","date":"2025-10-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":276,"price":12.58,"value":3472.08,"ownership":{"direct":true},"balance_after":16718.621,"source":{"system":"sec-edgar","filing":"0001193125-25-228649","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872069/000119312525228649/ownership.xml","form_type":"4"}},{"id":1027641,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Restricted Shares","published_at":"2025-10-02T21:15:04.000Z","date":"2025-10-01","kind":"exercise","planned":false,"acquired":false,"shares":250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Multiple restricted share grants are included in this total."}],"balance_after":7554,"derivative":{"underlying":"Common Stock","underlying_shares":250},"source":{"system":"sec-edgar","filing":"0001193125-25-228644","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000119312525228644/ownership.xml","form_type":"4"}},{"id":1027640,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Common Stock","published_at":"2025-10-02T21:15:04.000Z","date":"2025-10-01","kind":"exercise","planned":false,"acquired":true,"shares":250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8000.334,"source":{"system":"sec-edgar","filing":"0001193125-25-228644","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000119312525228644/ownership.xml","form_type":"4"}},{"id":1027639,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Common Stock","published_at":"2025-10-02T21:15:04.000Z","date":"2025-10-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":99,"price":12.58,"value":1245.42,"ownership":{"direct":true},"balance_after":7901.334,"source":{"system":"sec-edgar","filing":"0001193125-25-228644","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000119312525228644/ownership.xml","form_type":"4"}},{"id":1074828,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Restricted Shares","published_at":"2025-08-05T13:21:10.000Z","date":"2025-08-01","kind":"exercise","planned":false,"acquired":false,"shares":250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Multiple restricted share grants are included in this total."}],"balance_after":2150,"derivative":{"underlying":"Common Stock","underlying_shares":250},"source":{"system":"sec-edgar","filing":"0000950170-25-102465","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1872069/000095017025102465/ownership.xml","form_type":"4"}},{"id":1074827,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Common Stock","published_at":"2025-08-05T13:21:10.000Z","date":"2025-08-01","kind":"exercise","planned":false,"acquired":true,"shares":250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16393.621,"source":{"system":"sec-edgar","filing":"0000950170-25-102465","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1872069/000095017025102465/ownership.xml","form_type":"4"}},{"id":1074826,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Common Stock","published_at":"2025-08-05T13:21:10.000Z","date":"2025-08-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":99,"price":10.53,"value":1042.47,"ownership":{"direct":true},"balance_after":16294.621,"source":{"system":"sec-edgar","filing":"0000950170-25-102465","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872069/000095017025102465/ownership.xml","form_type":"4"}},{"id":1074989,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Restricted Shares","published_at":"2025-08-05T13:17:43.000Z","date":"2025-08-01","kind":"exercise","planned":false,"acquired":false,"shares":240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Multiple restricted share grants are included in this total."}],"balance_after":8004,"derivative":{"underlying":"Common Stock","underlying_shares":240},"source":{"system":"sec-edgar","filing":"0000950170-25-102459","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000095017025102459/ownership.xml","form_type":"4"}},{"id":1074988,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Restricted Shares","published_at":"2025-08-05T13:17:43.000Z","date":"2025-08-01","kind":"exercise","planned":false,"acquired":false,"shares":200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Multiple restricted share grants are included in this total."}],"balance_after":7804,"derivative":{"underlying":"Common Stock","underlying_shares":200},"source":{"system":"sec-edgar","filing":"0000950170-25-102459","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000095017025102459/ownership.xml","form_type":"4"}},{"id":1074987,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Common Stock","published_at":"2025-08-05T13:17:43.000Z","date":"2025-08-01","kind":"exercise","planned":false,"acquired":true,"shares":240,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7748.334,"source":{"system":"sec-edgar","filing":"0000950170-25-102459","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000095017025102459/ownership.xml","form_type":"4"}},{"id":1074986,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Common Stock","published_at":"2025-08-05T13:17:43.000Z","date":"2025-08-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":108,"price":10.53,"value":1137.24,"ownership":{"direct":true},"balance_after":7640.334,"source":{"system":"sec-edgar","filing":"0000950170-25-102459","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000095017025102459/ownership.xml","form_type":"4"}},{"id":1074985,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Common Stock","published_at":"2025-08-05T13:17:43.000Z","date":"2025-08-01","kind":"exercise","planned":false,"acquired":true,"shares":200,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7840.334,"source":{"system":"sec-edgar","filing":"0000950170-25-102459","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000095017025102459/ownership.xml","form_type":"4"}},{"id":1074984,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Common Stock","published_at":"2025-08-05T13:17:43.000Z","date":"2025-08-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":90,"price":10.53,"value":947.7,"ownership":{"direct":true},"balance_after":7750.334,"source":{"system":"sec-edgar","filing":"0000950170-25-102459","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000095017025102459/ownership.xml","form_type":"4"}},{"id":1159576,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Restricted Shares","published_at":"2025-05-05T18:55:21.000Z","date":"2025-05-01","kind":"exercise","planned":false,"acquired":false,"shares":175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Multiple restricted share grants are included in this total."}],"balance_after":8244,"derivative":{"underlying":"Common Stock","underlying_shares":175},"source":{"system":"sec-edgar","filing":"0000950170-25-063441","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000095017025063441/ownership.xml","form_type":"4"}},{"id":1159575,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Common Stock","published_at":"2025-05-05T18:55:21.000Z","date":"2025-05-01","kind":"exercise","planned":false,"acquired":true,"shares":175,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7587.334,"source":{"system":"sec-edgar","filing":"0000950170-25-063441","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000095017025063441/ownership.xml","form_type":"4"}},{"id":1159574,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Common Stock","published_at":"2025-05-05T18:55:21.000Z","date":"2025-05-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":79,"price":11.68,"value":922.72,"ownership":{"direct":true},"balance_after":7508.334,"source":{"system":"sec-edgar","filing":"0000950170-25-063441","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000095017025063441/ownership.xml","form_type":"4"}},{"id":1159450,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Restricted Shares","published_at":"2025-05-05T18:53:25.000Z","date":"2025-05-01","kind":"exercise","planned":false,"acquired":false,"shares":200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Multiple restricted share grants are included in this total."}],"balance_after":2650,"derivative":{"underlying":"Common Stock","underlying_shares":200},"source":{"system":"sec-edgar","filing":"0000950170-25-063437","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1872069/000095017025063437/ownership.xml","form_type":"4"}},{"id":1159449,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Restricted Shares","published_at":"2025-05-05T18:53:25.000Z","date":"2025-05-01","kind":"exercise","planned":false,"acquired":false,"shares":250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Multiple restricted share grants are included in this total."}],"balance_after":2400,"derivative":{"underlying":"Common Stock","underlying_shares":250},"source":{"system":"sec-edgar","filing":"0000950170-25-063437","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1872069/000095017025063437/ownership.xml","form_type":"4"}},{"id":1159448,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Common Stock","published_at":"2025-05-05T18:53:25.000Z","date":"2025-05-01","kind":"exercise","planned":false,"acquired":true,"shares":200,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16071.621,"source":{"system":"sec-edgar","filing":"0000950170-25-063437","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1872069/000095017025063437/ownership.xml","form_type":"4"}},{"id":1159447,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Common Stock","published_at":"2025-05-05T18:53:25.000Z","date":"2025-05-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":79,"price":11.68,"value":922.72,"ownership":{"direct":true},"balance_after":15992.621,"source":{"system":"sec-edgar","filing":"0000950170-25-063437","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1872069/000095017025063437/ownership.xml","form_type":"4"}},{"id":1159446,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Common Stock","published_at":"2025-05-05T18:53:25.000Z","date":"2025-05-01","kind":"exercise","planned":false,"acquired":true,"shares":250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16242.621,"source":{"system":"sec-edgar","filing":"0000950170-25-063437","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1872069/000095017025063437/ownership.xml","form_type":"4"}},{"id":1159445,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26699,"kind":"person","name":"Tattoli Mark Damian","position":1,"cik":"0001872069","reported_name":"Tattoli Mark Damian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Gen Counsel & Secretary"}}],"security":"Common Stock","published_at":"2025-05-05T18:53:25.000Z","date":"2025-05-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":99,"price":11.68,"value":1156.32,"ownership":{"direct":true},"balance_after":16143.621,"source":{"system":"sec-edgar","filing":"0000950170-25-063437","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872069/000095017025063437/ownership.xml","form_type":"4"}},{"id":1182233,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":53358,"kind":"person","name":"Temeng Kwaku","position":1,"cik":"0001846675","reported_name":"Temeng Kwaku","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Shares","published_at":"2025-04-02T18:40:47.000Z","date":"2025-04-01","kind":"exercise","planned":false,"acquired":false,"shares":9317,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2025."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":9317},"source":{"system":"sec-edgar","filing":"0000950170-25-049177","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1846675/000095017025049177/ownership.xml","form_type":"4"}},{"id":1182232,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":53358,"kind":"person","name":"Temeng Kwaku","position":1,"cik":"0001846675","reported_name":"Temeng Kwaku","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Shares","published_at":"2025-04-02T18:40:47.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":8069,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2026, subject to the terms of issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2026, subject to the terms of issuance."}],"balance_after":8069,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8069},"source":{"system":"sec-edgar","filing":"0000950170-25-049177","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1846675/000095017025049177/ownership.xml","form_type":"4"}},{"id":1182231,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":53358,"kind":"person","name":"Temeng Kwaku","position":1,"cik":"0001846675","reported_name":"Temeng Kwaku","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-02T18:40:47.000Z","date":"2025-04-01","kind":"exercise","planned":false,"acquired":true,"shares":9317,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":25528,"source":{"system":"sec-edgar","filing":"0000950170-25-049177","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1846675/000095017025049177/ownership.xml","form_type":"4"}},{"id":1182212,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":49429,"kind":"person","name":"Murray Katherine","position":1,"cik":"0001930744","reported_name":"Murray Katherine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Shares","published_at":"2025-04-02T18:39:29.000Z","date":"2025-04-01","kind":"exercise","planned":false,"acquired":false,"shares":9317,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2025."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":9317},"source":{"system":"sec-edgar","filing":"0000950170-25-049174","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1930744/000095017025049174/ownership.xml","form_type":"4"}},{"id":1182211,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":49429,"kind":"person","name":"Murray Katherine","position":1,"cik":"0001930744","reported_name":"Murray Katherine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Shares","published_at":"2025-04-02T18:39:29.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":8069,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2026, subject to the terms of issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2026, subject to the terms of issuance."}],"balance_after":8069,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8069},"source":{"system":"sec-edgar","filing":"0000950170-25-049174","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1930744/000095017025049174/ownership.xml","form_type":"4"}},{"id":1182210,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":49429,"kind":"person","name":"Murray Katherine","position":1,"cik":"0001930744","reported_name":"Murray Katherine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-02T18:39:29.000Z","date":"2025-04-01","kind":"exercise","planned":false,"acquired":true,"shares":9317,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":21221,"source":{"system":"sec-edgar","filing":"0000950170-25-049174","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1930744/000095017025049174/ownership.xml","form_type":"4"}},{"id":1182371,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":53365,"kind":"person","name":"Klingensmith Harvey Robert","position":1,"cik":"0001800107","reported_name":"Klingensmith Harvey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Shares","published_at":"2025-04-02T18:37:18.000Z","date":"2025-04-01","kind":"exercise","planned":false,"acquired":false,"shares":9317,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2025."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":9317},"source":{"system":"sec-edgar","filing":"0000950170-25-049169","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1800107/000095017025049169/ownership.xml","form_type":"4"}},{"id":1182370,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":53365,"kind":"person","name":"Klingensmith Harvey Robert","position":1,"cik":"0001800107","reported_name":"Klingensmith Harvey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Shares","published_at":"2025-04-02T18:37:18.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":8069,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2026, subject to the terms of issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2026, subject to the terms of issuance."}],"balance_after":8069,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8069},"source":{"system":"sec-edgar","filing":"0000950170-25-049169","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1800107/000095017025049169/ownership.xml","form_type":"4"}},{"id":1182369,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":53365,"kind":"person","name":"Klingensmith Harvey Robert","position":1,"cik":"0001800107","reported_name":"Klingensmith Harvey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-02T18:37:18.000Z","date":"2025-04-01","kind":"exercise","planned":false,"acquired":true,"shares":9317,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":41962,"source":{"system":"sec-edgar","filing":"0000950170-25-049169","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800107/000095017025049169/ownership.xml","form_type":"4"}},{"id":1183482,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":46460,"kind":"person","name":"Carnes Martha Z.","position":1,"cik":"0001678397","reported_name":"Carnes Martha Z.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Shares","published_at":"2025-04-02T18:36:09.000Z","date":"2025-04-01","kind":"exercise","planned":false,"acquired":false,"shares":9317,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2025."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":9317},"source":{"system":"sec-edgar","filing":"0000950170-25-049166","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1678397/000095017025049166/ownership.xml","form_type":"4"}},{"id":1183481,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":46460,"kind":"person","name":"Carnes Martha Z.","position":1,"cik":"0001678397","reported_name":"Carnes Martha Z.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Shares","published_at":"2025-04-02T18:36:09.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":8069,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2026, subject to the terms of issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2026, subject to the terms of issuance."}],"balance_after":8069,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8069},"source":{"system":"sec-edgar","filing":"0000950170-25-049166","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678397/000095017025049166/ownership.xml","form_type":"4"}},{"id":1183480,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":46460,"kind":"person","name":"Carnes Martha Z.","position":1,"cik":"0001678397","reported_name":"Carnes Martha Z.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-02T18:36:09.000Z","date":"2025-04-01","kind":"exercise","planned":false,"acquired":true,"shares":9317,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":46328,"source":{"system":"sec-edgar","filing":"0000950170-25-049166","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678397/000095017025049166/ownership.xml","form_type":"4"}},{"id":1184342,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":31865,"kind":"person","name":"ANASTASIO CURT","position":1,"cik":"0001032097","reported_name":"ANASTASIO CURT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Shares","published_at":"2025-04-02T18:34:53.000Z","date":"2025-04-01","kind":"exercise","planned":false,"acquired":false,"shares":9317,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2025."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":9317},"source":{"system":"sec-edgar","filing":"0000950170-25-049164","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1032097/000095017025049164/ownership.xml","form_type":"4"}},{"id":1184341,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":31865,"kind":"person","name":"ANASTASIO CURT","position":1,"cik":"0001032097","reported_name":"ANASTASIO CURT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Shares","published_at":"2025-04-02T18:34:53.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":8069,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2026, subject to the terms of issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2026, subject to the terms of issuance."}],"balance_after":8069,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8069},"source":{"system":"sec-edgar","filing":"0000950170-25-049164","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1032097/000095017025049164/ownership.xml","form_type":"4"}},{"id":1184340,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":31865,"kind":"person","name":"ANASTASIO CURT","position":1,"cik":"0001032097","reported_name":"ANASTASIO CURT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-02T18:34:53.000Z","date":"2025-04-01","kind":"exercise","planned":false,"acquired":true,"shares":9317,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15736,"source":{"system":"sec-edgar","filing":"0000950170-25-049164","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1032097/000095017025049164/ownership.xml","form_type":"4"}},{"id":1182461,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":81204,"kind":"person","name":"Straughen Michael","position":1,"cik":"0001677384","reported_name":"Straughen Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Shares","published_at":"2025-04-02T14:33:12.000Z","date":"2025-04-01","kind":"exercise","planned":false,"acquired":false,"shares":9317,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2025."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":9317},"source":{"system":"sec-edgar","filing":"0000950170-25-049157","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1677384/000095017025049157/ownership.xml","form_type":"4"}},{"id":1182460,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":81204,"kind":"person","name":"Straughen Michael","position":1,"cik":"0001677384","reported_name":"Straughen Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-02T14:33:12.000Z","date":"2025-04-01","kind":"exercise","planned":false,"acquired":true,"shares":9317,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":29186,"source":{"system":"sec-edgar","filing":"0000950170-25-049157","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1677384/000095017025049157/ownership.xml","form_type":"4"}},{"id":1182459,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":81204,"kind":"person","name":"Straughen Michael","position":1,"cik":"0001677384","reported_name":"Straughen Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-02T14:33:12.000Z","date":"2025-04-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":4634,"price":14.98,"value":69417.32,"ownership":{"direct":true},"balance_after":24552,"source":{"system":"sec-edgar","filing":"0000950170-25-049157","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1677384/000095017025049157/ownership.xml","form_type":"4"}},{"id":1269909,"issuer":{"id":5382,"kind":"organization","name":"Core Laboratories Inc. /DE/","symbol":"CLB"},"owners":[{"id":26723,"kind":"person","name":"Teo Sow Hang","position":1,"cik":"0002017091","reported_name":"Teo Sow Hang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO & Treasurer"}}],"security":"Performance Shares","published_at":"2025-02-13T21:45:20.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":7692,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Assuming the recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance criteria set forth below, this award will vest on January 1, 2028, following the conclusion of a three-year performance period that began on January 1, 2025 and ends on December 31, 2027 (the \"Performance Period\"). At the end of the Performance Period, 100% of the award will vest if the Company is in the top 55th percentile of Return on Invested Capital (\"ROIC\") among the Bloomberg Peer Group (\"BPG\"), and 200% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 55th and 85th percentile of ROIC (equivalent to 100% up to 200% of the award)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Assuming the recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance criteria set forth below, this award will vest on January 1, 2028, following the conclusion of a three-year performance period that began on January 1, 2025 and ends on December 31, 2027 (the \"Performance Period\"). At the end of the Performance Period, 100% of the award will vest if the Company is in the top 55th percentile of Return on Invested Capital (\"ROIC\") among the Bloomberg Peer Group (\"BPG\"), and 200% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 55th and 85th percentile of ROIC (equivalent to 100% up to 200% of the award)."}],"balance_after":7692,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7692},"source":{"system":"sec-edgar","filing":"0000950170-25-019977","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2017091/000095017025019977/ownership.xml","form_type":"4"}}],"next_cursor":"2025-02-13T21:45:20.000000Z,1269909"}